Literature DB >> 31152088

Conditioning intensity and antilymphocyte globulin: towards personalized transplant strategies?

Martin Bornhäuser1.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31152088      PMCID： PMC6545847          DOI： 10.3324/haematol.2019.216952

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

Review 1.  Application of machine learning algorithms for clinical predictive modeling: a data-mining approach in SCT.

Authors:  R Shouval; O Bondi; H Mishan; A Shimoni; R Unger; A Nagler
Journal:  Bone Marrow Transplant       Date:  2013-10-07       Impact factor: 5.483

2.  Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.

Authors:  Mohamed L Sorror; Brenda M Sandmaier; Barry E Storer; Georg N Franke; Ginna G Laport; Thomas R Chauncey; Edward Agura; Richard T Maziarz; Amelia Langston; Parameswaran Hari; Michael A Pulsipher; Wolfgang Bethge; Firoozeh Sahebi; Benedetto Bruno; Michael B Maris; Andrew Yeager; Finn Bo Petersen; Lars Vindeløv; Peter A McSweeney; Kai Hübel; Marco Mielcarek; George E Georges; Dietger Niederwieser; Karl G Blume; David G Maloney; Rainer Storb
Journal:  JAMA       Date:  2011-11-02       Impact factor: 56.272

3.  Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.

Authors:  Robert J Soiffer; Haesook T Kim; Joseph McGuirk; Mitchell E Horwitz; Laura Johnston; Mrinal M Patnaik; Witold Rybka; Andrew Artz; David L Porter; Thomas C Shea; Michael W Boyer; Richard T Maziarz; Paul J Shaughnessy; Usama Gergis; Hana Safah; Ran Reshef; John F DiPersio; Patrick J Stiff; Madhuri Vusirikala; Jeff Szer; Jennifer Holter; James D Levine; Paul J Martin; Joseph A Pidala; Ian D Lewis; Vincent T Ho; Edwin P Alyea; Jerome Ritz; Frank Glavin; Peter Westervelt; Madan H Jagasia; Yi-Bin Chen
Journal:  J Clin Oncol       Date:  2017-10-17       Impact factor: 44.544

4.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.

Authors:  S Slavin; A Nagler; E Naparstek; Y Kapelushnik; M Aker; G Cividalli; G Varadi; M Kirschbaum; A Ackerstein; S Samuel; A Amar; C Brautbar; O Ben-Tal; A Eldor; R Or
Journal:  Blood       Date:  1998-02-01       Impact factor: 22.113

Review 5.  Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects.

Authors:  A Bacigalupo
Journal:  Bone Marrow Transplant       Date:  2005-02       Impact factor: 5.483

6.  Optimizing Antithymocyte Globulin Dosing for Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Based on Recipient Absolute Lymphocyte Count.

Authors:  Vanessa E Kennedy; Heidi Chen; Bipin N Savani; John Greer; Adetola A Kassim; Brian G Engelhardt; Stacey Goodman; Salyka Sengsayadeth; Wichai Chinratanalab; Madan Jagasia
Journal:  Biol Blood Marrow Transplant       Date:  2017-08-30       Impact factor: 5.742

7.  Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.

Authors:  Jürgen Finke; Wolfgang A Bethge; Claudia Schmoor; Hellmut D Ottinger; Matthias Stelljes; Axel R Zander; Liisa Volin; Tapani Ruutu; Dominik A Heim; Rainer Schwerdtfeger; Karin Kolbe; Jiri Mayer; Johan A Maertens; Werner Linkesch; Ernst Holler; Vladimir Koza; Martin Bornhäuser; Hermann Einsele; Hans-Jochem Kolb; Hartmut Bertz; Matthias Egger; Olga Grishina; Gérard Socié
Journal:  Lancet Oncol       Date:  2009-08-18       Impact factor: 41.316

Review 8.  Total body irradiation before an allogeneic stem cell transplantation: is there a magic dose?

Authors:  Douglas R Adkins; John F DiPersio
Journal:  Curr Opin Hematol       Date:  2008-11       Impact factor: 3.284

9.  Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation.

Authors:  Christoph Schmid; Michael Schleuning; Rainer Schwerdtfeger; Bernd Hertenstein; Eva Mischak-Weissinger; Donald Bunjes; Stephanie V Harsdorf; Christoph Scheid; Udo Holtick; Hildegard Greinix; Felix Keil; Barbara Schneider; Michael Sandherr; Gesine Bug; Johanna Tischer; Georg Ledderose; Michael Hallek; Wolfgang Hiddemann; Hans-Jochem Kolb
Journal:  Blood       Date:  2006-03-21       Impact factor: 22.113

10.  Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis.

Authors:  Marie Robin; Sylvie Chevret; Linda Koster; Christine Wolschke; Ibrahim Yakoub-Agha; Jean Henri Bourhis; Patrice Chevallier; Jan J Cornelissen; Péter Reményi; Johan Maertens; Xavier Poiré; Charles Craddock; Gérard Socié; Maija Itälä-Remes; Harry C Schouten; Tony Marchand; Jakob Passweg; Didier Blaise; Gandhi Damaj; Zubeyde Nur Ozkurt; Tsila Zuckerman; Thomas Cluzeau; Hélène Labussière-Wallet; Jörg Cammenga; Donal McLornan; Yves Chalandon; Nicolaus Kröger
Journal:  Haematologica       Date:  2019-01-17       Impact factor: 9.941
View more
  1 in total

Review 1.  Application of machine learning in the management of acute myeloid leukemia: current practice and future prospects.

Authors:  Jan-Niklas Eckardt; Martin Bornhäuser; Karsten Wendt; Jan Moritz Middeke
Journal:  Blood Adv       Date:  2020-12-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.